{"id":14920,"date":"2024-11-25T21:02:16","date_gmt":"2024-11-25T13:02:16","guid":{"rendered":"https:\/\/flcube.com\/?p=14920"},"modified":"2024-11-25T21:02:22","modified_gmt":"2024-11-25T13:02:22","slug":"luye-pharmas-subsidiary-boan-biotech-strikes-licensing-deal-for-biosimilars-in-brazil","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14920","title":{"rendered":"Luye Pharma’s Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil"},"content":{"rendered":"\n

China-based Luye Pharma Group\u2019s (HKG: 2186<\/a>) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955<\/a>), has announced a licensing agreement with an unnamed Brazilian partner. The agreement grants the Brazilian company the rights to commercialize Boan Bio’s BA6101 and BA1102 in the local market as their Marketing Authorization Holder (MAH). Boan Bio will handle the commercial manufacturing of the drugs and will receive undisclosed upfront and milestone payments, in addition to sales commissions.<\/p>\n\n\n\n

Biosimilar Versions of Amgen’s Prolia and Xgeva<\/strong> BA6101 and BA1102 are biosimilar versions of the US major Amgen\u2019s Prolia (denosumab) and Xgeva (denosumab), respectively. Prolia is a widely used treatment for osteoporosis globally, while Xgeva is indicated for the treatment of solid tumor bone metastasis, multiple myeloma, giant cell tumor of bone, and hypercalcemia around the world.<\/p>\n\n\n\n

Implications of the Licensing Agreement<\/strong> This licensing agreement positions Boan Bio to expand its global footprint and tap into the Brazilian market with its biosimilar products. The partnership is expected to enhance patient access to these essential treatments in Brazil, potentially offering more affordable options to the local population.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Luye Pharma Group\u2019s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955),…<\/p>\n","protected":false},"author":1,"featured_media":14921,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[43,220,16,1023,1024,219],"class_list":["post-14920","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-biosimilars","tag-boan-biotechnology","tag-cancer","tag-hkg-2186","tag-hkg-6955","tag-luye-pharma"],"yoast_head":"\nLuye Pharma's Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Luye Pharma Group\u2019s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955), has announced a licensing agreement with an unnamed Brazilian partner. The agreement grants the Brazilian company the rights to commercialize Boan Bio's BA6101 and BA1102 in the local market as their Marketing Authorization Holder (MAH). Boan Bio will handle the commercial manufacturing of the drugs and will receive undisclosed upfront and milestone payments, in addition to sales commissions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14920\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Luye Pharma's Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14920\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-25T13:02:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-25T13:02:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/boan.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"455\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14920#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14920\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Luye Pharma’s Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil\",\"datePublished\":\"2024-11-25T13:02:16+00:00\",\"dateModified\":\"2024-11-25T13:02:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14920\"},\"wordCount\":198,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14920#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/boan.png\",\"keywords\":[\"Biosimilars\",\"Boan Biotechnology\",\"Cancer\",\"HKG: 2186\",\"HKG: 6955\",\"Luye Pharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14920#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14920\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14920\",\"name\":\"Luye Pharma's Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14920#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14920#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/boan.png\",\"datePublished\":\"2024-11-25T13:02:16+00:00\",\"dateModified\":\"2024-11-25T13:02:22+00:00\",\"description\":\"China-based Luye Pharma Group\u2019s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955), has announced a licensing agreement with an unnamed Brazilian partner. The agreement grants the Brazilian company the rights to commercialize Boan Bio's BA6101 and BA1102 in the local market as their Marketing Authorization Holder (MAH). Boan Bio will handle the commercial manufacturing of the drugs and will receive undisclosed upfront and milestone payments, in addition to sales commissions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14920#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14920\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14920#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/boan.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/boan.png\",\"width\":1080,\"height\":455,\"caption\":\"Luye Pharma's Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14920#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Luye Pharma’s Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Luye Pharma's Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil - Insight, China's Pharmaceutical Industry","description":"China-based Luye Pharma Group\u2019s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955), has announced a licensing agreement with an unnamed Brazilian partner. The agreement grants the Brazilian company the rights to commercialize Boan Bio's BA6101 and BA1102 in the local market as their Marketing Authorization Holder (MAH). Boan Bio will handle the commercial manufacturing of the drugs and will receive undisclosed upfront and milestone payments, in addition to sales commissions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14920","og_locale":"en_US","og_type":"article","og_title":"Luye Pharma's Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14920","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-25T13:02:16+00:00","article_modified_time":"2024-11-25T13:02:22+00:00","og_image":[{"width":1080,"height":455,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/boan.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14920#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14920"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Luye Pharma’s Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil","datePublished":"2024-11-25T13:02:16+00:00","dateModified":"2024-11-25T13:02:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14920"},"wordCount":198,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=14920#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/boan.png","keywords":["Biosimilars","Boan Biotechnology","Cancer","HKG: 2186","HKG: 6955","Luye Pharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14920#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14920","url":"https:\/\/flcube.com\/?p=14920","name":"Luye Pharma's Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=14920#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=14920#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/boan.png","datePublished":"2024-11-25T13:02:16+00:00","dateModified":"2024-11-25T13:02:22+00:00","description":"China-based Luye Pharma Group\u2019s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955), has announced a licensing agreement with an unnamed Brazilian partner. The agreement grants the Brazilian company the rights to commercialize Boan Bio's BA6101 and BA1102 in the local market as their Marketing Authorization Holder (MAH). Boan Bio will handle the commercial manufacturing of the drugs and will receive undisclosed upfront and milestone payments, in addition to sales commissions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14920#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14920"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=14920#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/boan.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/boan.png","width":1080,"height":455,"caption":"Luye Pharma's Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14920#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Luye Pharma’s Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/boan.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14920"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14920\/revisions"}],"predecessor-version":[{"id":14922,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14920\/revisions\/14922"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/14921"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}